137 related articles for article (PubMed ID: 1379102)
1. P53 and Ki-67 immunoreactivity in human prostate cancer and benign hyperplasia.
Thompson SJ; Mellon K; Charlton RG; Marsh C; Robinson M; Neal DE
Br J Urol; 1992 Jun; 69(6):609-13. PubMed ID: 1379102
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical determination of p53 protein in prostatic cancer and prostatic intraepithelial neoplasms.
Yaman O; Ozdiler E; Orhan D; Sak SD; Baltaci S; Tulunay O; Göğüş O
Urol Int; 1997; 58(4):199-202. PubMed ID: 9253117
[TBL] [Abstract][Full Text] [Related]
3. Ki-67 antigen and P53 protein expression in benign and malignant prostatic lesions. Immunohistochemical quantitative study.
Sasor A; Wagrowska-Danilewicz M; Danilewicz M
Pol J Pathol; 2000; 51(1):31-6. PubMed ID: 10833901
[TBL] [Abstract][Full Text] [Related]
4. p53, c-erbB-2 and the epidermal growth factor receptor in the benign and malignant prostate.
Mellon K; Thompson S; Charlton RG; Marsh C; Robinson M; Lane DP; Harris AL; Horne CH; Neal DE
J Urol; 1992 Feb; 147(2):496-9. PubMed ID: 1370701
[TBL] [Abstract][Full Text] [Related]
5. Ki-67 and PCNA expression in prostate cancer and benign prostatic hyperplasia.
Zhong W; Peng J; He H; Wu D; Han Z; Bi X; Dai Q
Clin Invest Med; 2008; 31(1):E8-E15. PubMed ID: 18312749
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical expression of retinoblastoma and p53 tumor suppressor genes in prostatic intraepithelial neoplasia: comparison with prostatic adenocarcinoma and benign prostate.
Tamboli P; Amin MB; Xu HJ; Linden MD
Mod Pathol; 1998 Mar; 11(3):247-52. PubMed ID: 9521470
[TBL] [Abstract][Full Text] [Related]
7. Accumulation of p53 and expression of CD44 in human prostatic cancer and benign prostatic hyperplasia: an immunohistochemical study.
Zhang XH; Sakamoto H; Takenaka I
Br J Urol; 1996 Mar; 77(3):441-4. PubMed ID: 8814853
[TBL] [Abstract][Full Text] [Related]
8. Interferon-gamma and its functional receptors overexpression in benign prostatic hyperplasia and prostatic carcinoma: parallelism with c-myc and p53 expression.
Royuela M; de Miguel MP; Ruiz A; Fraile B; Arenas MI; Romo E; Paniagua R
Eur Cytokine Netw; 2000 Mar; 11(1):119-27. PubMed ID: 10705309
[TBL] [Abstract][Full Text] [Related]
9. p53 accumulation associated with bcl-2, the proliferation marker MIB-1 and survival in patients with prostate cancer subjected to watchful waiting.
Borre M; Stausbol-Gron B; Overgaard J
J Urol; 2000 Sep; 164(3 Pt 1):716-21. PubMed ID: 10953132
[TBL] [Abstract][Full Text] [Related]
10. Correlation of genetic and immunodetection of TP53 mutations in malignant and benign prostate tissues.
Wertz IE; Deitch AD; Gumerlock PH; Gandour-Edwards R; Chi SG; de Vere White RW
Hum Pathol; 1996 Jun; 27(6):573-80. PubMed ID: 8666367
[TBL] [Abstract][Full Text] [Related]
11. p53 expression and clinical outcome in prostate cancer.
Thomas DJ; Robinson M; King P; Hasan T; Charlton R; Martin J; Carr TW; Neal DE
Br J Urol; 1993 Nov; 72(5 Pt 2):778-81. PubMed ID: 8281412
[TBL] [Abstract][Full Text] [Related]
12. p53 protein overexpression is associated with increased cell proliferation in patients with locally recurrent prostate carcinoma after radiation therapy.
Cheng L; Sebo TJ; Cheville JC; Pisansky TM; Slezak J; Bergstralh EJ; Pacelli A; Neumann RM; Zincke H; Bostwick DG
Cancer; 1999 Mar; 85(6):1293-9. PubMed ID: 10189134
[TBL] [Abstract][Full Text] [Related]
13. Expression of hypoxia-inducible factor 1alpha in human normal, benign, and malignant prostate tissue.
Du Z; Fujiyama C; Chen Y; Masaki Z
Chin Med J (Engl); 2003 Dec; 116(12):1936-9. PubMed ID: 14687488
[TBL] [Abstract][Full Text] [Related]
14. Frequency of Ki-67 (MIB-1) and P53 expressions among patients with prostate cancer.
Madani SH; Ameli S; Khazaei S; Kanani M; Izadi B
Indian J Pathol Microbiol; 2011; 54(4):688-91. PubMed ID: 22234091
[TBL] [Abstract][Full Text] [Related]
15. Altered expression of p53, but not Rb, is involved in canine prostatic carcinogenesis.
Pagliarone S; Frattone L; Pirocchi V; Della Salda L; Palmieri C
Res Vet Sci; 2016 Apr; 105():195-9. PubMed ID: 27033932
[TBL] [Abstract][Full Text] [Related]
16. Determining prognosis of clinically localized prostate cancer by immunohistochemical detection of mutant p53.
Stricker HJ; Jay JK; Linden MD; Tamboli P; Amin MB
Urology; 1996 Mar; 47(3):366-9. PubMed ID: 8633403
[TBL] [Abstract][Full Text] [Related]
17. An immunocytochemical analysis of TGF alpha expression in benign and malignant prostatic tumors.
Harper ME; Goddard L; Glynne-Jones E; Wilson DW; Price-Thomas M; Peeling WB; Griffiths K
Prostate; 1993; 23(1):9-23. PubMed ID: 7687782
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical evaluation of PCNA, p53, HSP60, HSP10 and MUC-2 presence and expression in prostate carcinogenesis.
Cappello F; Rappa F; David S; Anzalone R; Zummo G
Anticancer Res; 2003; 23(2B):1325-31. PubMed ID: 12820390
[TBL] [Abstract][Full Text] [Related]
19. Glycoprotein A-80 in the human prostate: immunolocalization in prostatic intraepithelial neoplasia, carcinoma, radiation failure, and after neoadjuvant hormonal therapy.
Coogan CL; Bostwick DG; Bloom KJ; Gould VE
Urology; 2003 Jan; 61(1):248-52. PubMed ID: 12559317
[TBL] [Abstract][Full Text] [Related]
20. An evaluation of the markers p53 and Ki-67 for their predictive value in prostate cancer.
Uzoaru I; Rubenstein M; Mirochnik Y; Slobodskoy L; Shaw M; Guinan P
J Surg Oncol; 1998 Jan; 67(1):33-7. PubMed ID: 9457254
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
